Scope
This focused NICE guidance covers people over 16 with obstructive sleep apnoea/hypopnoea syndrome (OSAHS), obesity hypoventilation syndrome (OHS) or COPD–OSAHS overlap. Diagnosis depends on sleep testing and, when hypoventilation is suspected, awake blood gases. Treatment choices distinguish uncomplicated obstructive events from persistent hypercapnia or acute ventilatory failure, with structured monitoring and support for adherence.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Recognise symptoms and prioritise assessment
- Assess for OSAHS when at least 2 compatible features occur, such as snoring, witnessed apnoeas, unrefreshing sleep, morning headache, unexplained sleepiness/fatigue, nocturia, nocturnal choking, fragmented sleep or cognitive problems. [1]
- Use the Epworth scale to assess sleepiness and consider STOP-Bang as an additional tool. Do not use Epworth alone to decide referral, because OSAHS can occur without excessive sleepiness. [1]
- Prioritise rapid OSAHS assessment for vocational drivers, safety-critical workers, unstable cardiovascular disease, pregnancy, assessment before major surgery or non-arteritic anterior ischaemic optic neuropathy. Include functional sleepiness, comorbidity and occupational risk in referrals. [1]
Confirm OSAHS with appropriate sleep testing
- Offer home respiratory polygraphy for suspected OSAHS. If access is limited, consider home oximetry, recognising that heart failure or chronic lung disease can make oximetry unreliable for distinguishing obstructive sleep apnoea from other hypoxaemia. [1]
- If oximetry is negative but symptoms are significant, consider polygraphy or polysomnography; if polygraphy is negative but symptoms persist, consider polysomnography. Consider hospital polygraphy when home tests are impractical or additional monitoring is required. [1]
- Use sleep-study results to establish diagnosis and severity. The guideline defines mild OSAHS as AHI 5 to below 15, moderate as 15 to below 30, and severe as 30 or more events per hour. [1]
Match OSAHS treatment to symptoms and severity
- Discuss weight management, smoking cessation, reduced alcohol intake and sleep hygiene for all OSAHS severities. Mild disease without symptoms affecting usual daytime activity generally does not require treatment beyond lifestyle and sleep advice. [1]
- For mild OSAHS affecting quality of life and daytime activity, offer fixed CPAP when lifestyle advice fails or is inappropriate, or concurrently with lifestyle advice for priority groups needing rapid assessment. Those groups include vocational/safety-critical work, unstable cardiovascular disease, pregnancy, major-surgery assessment and non-arteritic anterior ischaemic optic neuropathy. [1]
- Offer fixed CPAP plus lifestyle advice for moderate or severe OSAHS. Consider auto-CPAP when fixed pressure is intolerable, high pressure is needed only intermittently, telemonitoring is technologically impossible, or a sustained equal/lower-cost option is available. [1]
- For OSAHS when CPAP is declined or intolerable, consider a customised or semi-customised mandibular advancement splint from age 18 with optimal dental and periodontal health; in mild disease, symptoms must affect daytime activities. Semi-customised devices may be unsuitable with active dental/periodontal disease, few teeth or generalised tonic-clonic seizures. [1]
- Consider positional modifiers for mild/moderate positional OSAHS when other treatments are unsuitable or intolerable; they are unlikely to help severe disease. Consider tonsillectomy for large obstructive tonsils with BMI below 35 kg/m², or specialist surgical assessment for severe OSAHS after supervised failure to tolerate both CPAP and a customised splint. [1]
Identify and treat obesity hypoventilation separately
- Suspect OHS with BMI at least 30 kg/m² plus OSAHS features or nocturnal-hypoventilation clues such as waking headache, oedema, room-air saturation below 94% or unexplained polycythaemia. Do not rely on Epworth alone for referral. [1]
- With low pretest probability of OHS, consider venous bicarbonate; below 27 mmol/L makes OHS unlikely. For suspected OHS, measure awake arterial or arterialised capillary blood gases to diagnose ventilatory failure, and do not delay acute-failure treatment for further tests. [1]
- For suspected OHS, offer respiratory polygraphy to determine associated OSAHS and consider added transcutaneous carbon-dioxide monitoring for nocturnal hypoventilation. Do not diagnose the obstructive component using oximetry alone. [1]
- For OHS without acute ventilatory failure and with severe OSAHS, offer CPAP first-line. Offer non-invasive ventilation if symptoms or hypercapnia persist, AHI/ODI remain inadequately reduced, or CPAP is poorly tolerated. Consider NIV for nocturnal hypoventilation without severe OSAHS. [1]
- Offer NIV for OHS with acute ventilatory failure. If hypercapnia persists, consider continuing and optimising NIV; if it resolves, consider stopping with monitoring. After stabilisation on NIV with control of hypercapnia, consider stopping NIV for respiratory polygraphy and a CPAP trial in patients with frequent obstructive events and minimal hypoventilation; restart NIV if they decompensate after withdrawal. [1]
Account for COPD and carbon-dioxide retention
- For suspected COPD–OSAHS overlap, assess awake blood gases and offer polygraphy; consider transcutaneous carbon-dioxide monitoring during sleep. Do not use oximetry alone to diagnose OSAHS or nocturnal hypoventilation, and do not delay treatment of acute ventilatory failure. [1]
- For COPD–OSAHS overlap without severe hypercapnia, consider CPAP first-line when PaCO₂ is 7.0 kPa or less. With nocturnal hypoventilation and PaCO₂ above 7.0 kPa, consider NIV instead. [1]
- For OHS or COPD–OSAHS overlap, consider supplemental oxygen only with persistent hypoxaemia despite optimised CPAP/NIV control of apnoea and nocturnal hypoventilation. Address other causes and reassess oxygen need after ventilatory treatment is optimised. [1]
Measure response and support adherence
- Review OSAHS CPAP treatment within 1 month and continue until symptoms and AHI/ODI are optimised; then consider annual follow-up. Provide access to sleep-service advice, support and equipment between visits. [1]
- During OSAHS treatment, assess symptoms and vigilance, AHI/ODI, adherence and available device data. For CPAP, also review mask fit and leak, dryness, other causes of disturbed sleep, sleep hygiene and equipment care. [1]
- For OHS or COPD overlap using CPAP/NIV, review within 1 month and continue until symptoms, sleep indices, oxygenation and hypercapnia improve. Once optimised and controlled, consider 6-monthly to annual follow-up according to need. [1]
- Provide education and practical support for adherence, tailored to preferences, from trained staff at treatment start and follow-up. Explain the effect of sleepiness on driving and safety-critical work and the need for appropriate local fitness-to-drive assessment. [1]
Limitations and use
- The guideline is for people over 16; these diagnostic and ventilation pathways must not be used as paediatric guidance. Device pressures, titration and acute-ventilation protocols require specialist assessment and are not specified here.
- The full rhinitis, surgery, device-adjustment and treatment-withdrawal pathways are not reproduced. Treatment effects and oxygen needs require review rather than assuming success from a device prescription.
- UK driving notification, reimbursement and service arrangements need local adaptation in India; the clinical guidance does not itself establish local legal driving clearance.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s
Selected recommendation material consulted
Publication details
- Issuing organisation
- NICE
- First published
- 20 August 2021
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.